Use este identificador para citar ou linkar para este item:
https://repositorio.unichristus.edu.br/jspui/handle/123456789/1950Registro completo de metadados
| Campo DC | Valor | Idioma |
|---|---|---|
| dc.contributor.advisor | Silva, Paulo Goberlânio de Barros | - |
| dc.contributor.author | Aragão, André da Rocha | - |
| dc.date.accessioned | 2025-07-04T17:39:12Z | - |
| dc.date.available | 2025-07-04T17:39:12Z | - |
| dc.date.issued | 2025-06-17 | - |
| dc.identifier.uri | https://repositorio.unichristus.edu.br/jspui/handle/123456789/1950 | - |
| dc.description | ALROWIS, R. et al. Medication-related osteonecrosis of the jaw (MRONJ): A review of pathophysiology, risk factors, preventive measures and treatment strategies. The Saudi Dental Journal, 2022. AL-SALIH, A.; DAM, A.; LINDBERG, P.; TRUEDSSON, A. Medication-related osteonecrosis of the jaws initiated by zoledronic acid and potential pathophysiology. Dentistry Journal, v. 9, n. 8, p. 85, 2021. DOI: https://doi.org/10.3390/dj9080085. BROZOSKI, M. et al. Bisphosphonate-related osteonecrosis of the jaw. Revista Brasileira de Reumatologia, v. 52, p. 265–270, 2012. CREMERS, S. et al. Pharmacology of bisphosphonates. British Journal of Clinical Pharmacology, v. 85, n. 6, p. 1052–1062, 2019. DOI: 10.1111/bcp.13867. DATTA, H. K. et al. The cell biology of bone metabolism. Journal of Clinical Pathology, v. 61, n. 5, p. 577–587, 2008. DOI: 10.1136/jcp.2007.048868. DE BARROS SILVA, P. G. et al. Immune cellular profile of bisphosphonate-related osteonecrosis of the jaw. Oral Diseases, v. 22, n. 7, p. 649–657, 2016. DOI: 10.1111/odi.12513. DI PAOLA, R. et al. Effect of aminoguanidine in ligature-induced periodontitis in rats. Journal of Dental Research, 2004. DINIZ-FREITAS, M. et al. Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction. Medicina Oral, Patologia Oral y Cirugía Bucal, v. 17, n. 4, p. e601, 2012. ENDO, Y. et al. Basic studies on the mechanism, prevention, and treatment of osteonecrosis of the jaw induced by bisphosphonates. Yakugaku Zasshi, v. 140, n. 1, p. 63–79, 2020. DOI: 10.1248/yakushi.19-00125. FAVIA, G. et al. Medication‐related osteonecrosis of the jaw: surgical or non‐surgical treatment? Oral Diseases, v. 24, n. 1-2, p. 238–242, 2018. FOX, S. W.; CHOW, J. W. M. Expressão do óxido nítrico sintase em células ósseas. Bone, v. 23, n. 1, p. 1–6, 1998. DOI: 10.1016/s8756-3282(98)00070-2. GERSTENFELD, L. C. et al. Fracture healing as a post‐natal developmental process: molecular, spatial, and temporal aspects of its regulation. Journal of Cellular Biochemistry, v. 88, n. 5, p. 873–884, 2003. GUIMARÃES, R. P. et al. Effects of induced diabetes and the administration of aminoguanidine in the biomechanical retention of implants: a study in rats. Journal of Periodontal Research, v. 46, n. 6, 2011. HANLEY, D. A. Biochemical markers of bone turnover. In: HENDERSON, J. E.; GOLTZMAN, D. (ed.). The osteoporosis primer. Cambridge: University Press, 2000. p. 239–252. KIM, J. M. et al. Osteoblast-osteoclast communication and bone homeostasis. Cells, v. 9, n. 9, p. 2073, 2020. DOI: 10.3390/cells9092073. KIM, D. et al. Changes in periodontium after extraction of a periodontally-involved tooth in rats. Journal of Periodontal & Implant Science, v. 42, n. 5, p. 158–165, 2012. MARX, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery, v. 61, n. 9, p. 1115–1117, 2003. MIGLIORATI, C. A.; BRENNAN, M. T.; PETERSON, D. E. Medication-related osteonecrosis of the jaws. JNCI Monographs, v. 2019, n. 53, p. lgz009, 2019. MOSTAFA, A. M. et al. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats. Research Communications in Molecular Pathology and Pharmacology, v. 106, n. 3, p. 193–202, 1999. MURATSU, D. et al. Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages. PLoS ONE, v. 8, n. 7, p. e67906, 2013. PAOLA, R. et al. Effect of aminoguanidine in ligature-induced periodontitis in rats. Journal of Dental Research, v. 83, n. 4, 2004. PINTO, M. R. Role of induced nitric oxide synthases in orofacial nociception/discomfort after dental tooth bleaching with hydrogen peroxide. Archives of Oral Biology, v. 160, 2024. DOI: 10.1016/j.archoralbio.2024.105937. ROSELLA, D. et al. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. Journal of International Society of Preventive & Community Dentistry, v. 6, n. 2, p. 97–104, 2016. DOI: 10.4103/2231-0762.178742. RUGGIERO, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. Journal of Oral and Maxillofacial Surgery, v. 72, n. 10, p. 1938–1956, 2014. SAMBROOK, F.; COOPER, C. Osteoporosis. Current Therapeutics, v. 42, n. 12–1, 2001. SHIBAHARA, T. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. The Tohoku Journal of Experimental Medicine, v. 247, n. 2, p. 75–86, 2019. SILVA, P. G. B. et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Archives of Oral Biology, v. 60, n. 9, p. 1237–1245, 2015. SINGH, M. et al. Effect of pyridoxine on toxicity of aminoguanidine and its neuroprotective effect in aluminum chloride induced dementia in rats. Asian Journal of Pharmacy and Pharmacology, v. 4, n. 2, p. 184–191, 2018. DOI: 10.31024/ajpp.2018.4.2.14. STEVANOVIĆ, I. et al. The effect of aminoguanidine, an inducible nitric oxide synthase inhibitor, on AlCl3 toxicity in the rat hippocampus. Archives of Biological Sciences, v. 62, n. 4, p. 981–991, 2010. DOI: 10.2298/abs1004981s. SUZUKI, A. et al. Role of metabolism in bone development and homeostasis. International Journal of Molecular Sciences, v. 21, n. 23, p. 8992, 2020. DOI: 10.3390/ijms21238992. TOBEIHA, M. et al. RANKL/RANK/OPG pathway: A mechanism involved in exercise-induced bone remodeling. BioMed Research International, v. 2020, p. 6910312, 2020. DOI: 10.1155/2020/6910312. TSUKAHARA, H. et al. Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. American Journal of Physiology-Endocrinology and Metabolism, v. 270, n. 5, p. E840–E845, 1996. DOI: 10.1152/ajpendo.1996.270.5.e840. VALACHIS, A. et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis. The Oncologist, v. 18, n. 4, p. 353–361, 2013. DOI: 10.1634/theoncologist.2012-0261. VAN’T HOF, R. J.; RALSTON, S. H. Nitric oxide and bone. Immunology, v. 103, n. 3, p. 255–261, 2001. DOI: 10.1046/j.1365-2567.2001.01261.x. VERDE, M. E. et al. Effect of bisphosphonates on the levels of Rankl and Opg in gingival crevicular fluid of patients with periodontal disease and post-menopausal osteoporosis. Acta Odontológica Latinoamericana, v. 28, n. 3, p. 215–221, 2015. WYNGAERT, T. et al. Rank ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): Non bis in idem? Supportive Care in Cancer, v. 19, n. 12, p. 2035–2040, 2011. DOI: 10.1007/s00520-010-1061-0. ZHAO, J. et al. Local administration of zoledronic acid prevents traumatic osteonecrosis of the femoral head in rat models. Journal of Orthopaedic Translation, v. 27, p. 132–138, 2021. DOI: 10.1016/j.jot.2020.08.005. | pt_BR |
| dc.description.abstract | Introdução: A osteonecrose dos maxilares induzida por bisfosfonatos (OMB) é um grave efeito adverso da terapia com bisfosfonatos, em especial o Ácido Zoledrônico (AZ) e está diretamente relacionada a estresse oxidativo. Objetivo: Avaliar a influência do bloqueio da Óxido Nítrico Sintase induzida (iNOS) no controle da OMB em ratos tratados com AZ. Materiais e métodos: Para isso foram selecionados 48 ratos Wistar machos que foram divididos em um grupo controle negativo tratado com solução salina e.v, um grupo controle positivo, tratado com 0,2mg/kg de AZ e.v., um grupo controle aminoguanidina tratado com 200 mg/kg de aminoguanidina e três grupos testes tratados com AZ e co-tratados com aminoguanidina 50, 100 e 200mg/kg s.c três vezes por semana desde o início do protocolo até o final do estudo. Quatro semanas após as três administrações semanais consecutivas de AZ os animais foram submetidos a exodontia dos primeiros molares inferiores esquerdos e na semana seguinte, dose adicional de AZ foi administrada. A eutanásia foi realizada quatro semanas após exodontia (dia 70) e as mandíbulas foram removidas para análise radiomorfométrica da área sugestiva de OMB e análise histomorfométrica (contagem de lacunas de osteócitos vazias, osteoclastos viáveis e apoptóticos e células inflamatórias polimorfonucleares e mononucleares). Teste ANOVA/Bonferroni foi utilizado para análise estatística (p<0,05, GraphPad Prism 5.0). Resultados: Os animais do grupo AMG.200 e os animais dos grupos AZ+AMG.100 e AZ+AMG.200 mostraram redução significativa do ganho de massa corporal comparados com os grupos salina e AZ (p<0,001). Os animais do grupo AZ apresentaram aumento do percentual de lacunas osteócitos vazios e os grupos AZ+AMG.100 e AZ+AMG.200 mostraram retorno aos níveis basais (p<0,001). A contagem de osteoclastos também foi aumentada no grupo AZ e os grupos AZ+AMG.100 e AZ+AMG.200 mostraram retorno aos níveis basais (p=0,006) e a contagem de PMN foi aumentada no grupo AZ e reduzida em todos os grupos AZ+AMG (p=0,045). Não houve diferença significativa na contagem de MN (p=0,864). Conclusão: O tratamento com aminoguanidina reverte a OMB, mas possui toxicidade sistêmica significativa. | pt_BR |
| dc.subject | Bisfosfonatos | pt_BR |
| dc.subject | Osteonecrose dos maxilares induzida por medicamentos | pt_BR |
| dc.subject | inflamação | pt_BR |
| dc.title | INFLUÊNCIA DO BLOQUEIO DA ÓXIDO NÍTRICO SINTASE INDUZIDA POR AMINOGUANIDINA NA SEVERIDADE DE OSTEONECROSE DOS MAXILARES INDUZIDA POR ÁCIDO ZOLEDRÔNICO EM RATOS | pt_BR |
| dc.type | TCC | pt_BR |
| dc.title.ingles | INFLUENCE OF AMINOGUANIDINE-INDUCED NITRIC OXIDE SYNTHASE BLOCKADE ON THE SEVERITY OF ZOLEDRONIC ACID-INDUCED JAW OSTEONECROSIS IN RATS | pt_BR |
| dc.description.resumo_abstract | Introduction: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe adverse effect associated with bisphosphonate therapy, particularly with Zoledronic Acid (ZA), and is directly linked to oxidative stress. Objective: To evaluate the influence of inducible nitric oxide synthase (iNOS) inhibition on the control of BRONJ in rats treated with ZA. Materials and Methods: Forty-eight male Wistar rats were selected and allocated into the following groups: a negative control group treated with intravenous saline solution; a positive control group treated with 0.2 mg/kg of ZA intravenously; an aminoguanidine (AMG) control group treated with 200 mg/kg AMG; and three experimental groups treated with ZA and co-treated with AMG at doses of 50, 100 and 200mg/kg subcutaneously, three times per week from the beginning of the protocol until the end of the study. Four weeks after three consecutive weekly administrations of ZA, the animals underwent extraction of the left mandibular first molars. In the following week, an additional dose of ZA was administered. Euthanasia was performed four weeks post-extraction (day 70), and mandibles were harvested for radiomorphometric analysis of the suspected BRONJ area and histomorphometric evaluation (quantification of empty osteocyte lacunae, viable and apoptotic osteoclasts, and polymorphonuclear and mononuclear inflammatory cells). ANOVA followed by Bonferroni post-hoc test was used for statistical analysis (p<0.05, GraphPad Prism 5.0). Results: Animals in the AMG.200 group and those in the AZ+AMG.100 and AZ+AMG.200 groups exhibited a significant reduction in body mass gain compared to the saline and ZA groups (p<0.001). The ZA group demonstrated an increased percentage of empty osteocyte lacunae, whereas the AZ+AMG.100 and AZ+AMG.200 groups showed a return to baseline levels (p<0.001). Osteoclast counts were elevated in the ZA group but returned to baseline in the AZ+AMG.100 and AZ+AMG.200 groups (p=0.006). Polymorphonuclear cell count was increased in the ZA group and reduced in all AZ+AMG groups (p=0.045), while mononuclear cell count showed no significant differences (p=0.864). Conclusion: Aminoguanidine treatment reverses BRONJ; however, it is associated with significant systemic toxicity. | pt_BR |
| Aparece nas coleções: | Odontologia - Campus PARQUE ECOLÓGICO | |
Arquivos associados a este item:
| Arquivo | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| AndréAragão.pdf | 886,67 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.